Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143101 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT03143101 is a Phase 4 study that has completed, run by MedImmune. The registered enrollment target is 200 participants.
The verdict
NCT03143101, a Phase 4 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the previous A/H1N1 strain that was included in the vaccine in the 2015-2016 influenza season.
Interventions
- BIOLOGICAL FluMist trivalent (2015-2016)
- BIOLOGICAL FluMist Quadrivalent (2015-2016)
- BIOLOGICAL FluMist Quadrivalent (2017-2018)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2017-09-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03143101
The ClinicalTrials.gov registry entry for NCT03143101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FluMist trivalent (2015-2016) is the first listed.
NCT03143101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03143101 about?
NCT03143101 is a clinical study titled "Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age". This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the previous A/H1N1 strain that was included in the vaccine in the 2015-2016 infl...
What is the current status of trial NCT03143101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2017-05-08. Estimated completion is 2017-09-29.
What interventions are being tested in trial NCT03143101?
The interventions under investigation include: FluMist trivalent (2015-2016) (BIOLOGICAL), FluMist Quadrivalent (2015-2016) (BIOLOGICAL), FluMist Quadrivalent (2017-2018) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03143101?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.